Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Intensity, Brief-Duration Chemotherapy in Relapsed/Refractory ALL
NCT00002865Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Apr 1995
- Primary completion
- Jun 2000
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Covalent Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, methotrexate, vincristine, doxorubicin, dexamethasone in acute lymphoblastic leukemia (ALL), sponsored by Wake Forest University Health Sciences. Started Apr 1995; status: completed.
02
Drugs
cyclophosphamidemethotrexatevincristinedoxorubicindexamethasone
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00002865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002865.